| Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. | |
| | |
MedLine Citation:
|
PMID: 20971812 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Despite recent improvements in therapeutic management of osteosarcoma, ongoing challenges in improving the response to chemotherapy warrants new strategies still needed to improve overall patient survival. In this study, we investigated in vivo the effects of RAD001 (Everolimus), a new orally available mTOR inhibitor, on the growth of human and mouse osteosarcoma cells either alone or in combination with zoledronate (ZOL), an anti-osteoporotic drug used to treat bone metastases. RAD001 inhibited osteosarcoma cell proliferation in a dose- and time-dependent manner with no modification of cell-cycle distribution. Combination with ZOL augmented this inhibition of cell proliferation, decreasing PI3K/mTOR signaling compared with single treatments. Notably, in contrast to RAD001, ZOL downregulated isoprenylated membrane-bound Ras concomitantly with an increase of nonisoprenylated cytosolic Ras in sensitive and resistant osteosarcoma cell lines to both drugs. Moreover, ZOL and RAD001 synergized to decrease Ras isoprenylation and GTP-bound Ras levels. Further, the drug combination reduced tumor development in two murine models of osteoblastic or osteolytic osteosarcoma. We found that ZOL could reverse RAD001 resistance in osteosarcoma, limiting osteosarcoma cell growth in combination with RAD001. Our findings rationalize further study of the applications of mTOR and mevalonate pathway inhibitors that can limit protein prenylation pathways. |
| | |
Authors:
|
Gatien Moriceau; Benjamin Ory; Laura Mitrofan; Chiara Riganti; Frédéric Blanchard; Régis Brion; Céline Charrier; Séverine Battaglia; Paul Pilet; Marc G Denis; Leonard D Shultz; Jukka Mönkkönen; Françoise Rédini; Dominique Heymann |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2010-10-22 |
Journal Detail:
|
Title: Cancer research Volume: 70 ISSN: 1538-7445 ISO Abbreviation: Cancer Res. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-12-16 Completed Date: 2011-01-20 Revised Date: 2011-12-19 |
Medline Journal Info:
|
Nlm Unique ID: 2984705R Medline TA: Cancer Res Country: United States |
Other Details:
|
Languages: eng Pagination: 10329-39 Citation Subset: IM |
Copyright Information:
|
©2010 AACR. |
Affiliation:
|
INSERM, UMR 957, Nantes, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Bone Density Conservation Agents / pharmacology Bone Neoplasms / drug therapy*, metabolism, pathology Cell Growth Processes / drug effects Cell Line, Tumor Diphosphonates / pharmacology* Drug Resistance, Neoplasm Drug Synergism Humans Imidazoles / pharmacology* Male Mice Mice, Inbred C3H Mice, Inbred C57BL Osteosarcoma / drug therapy*, metabolism, pathology Protein Prenylation / drug effects Rats Sirolimus / analogs & derivatives*, pharmacology TOR Serine-Threonine Kinases / metabolism* ras Proteins / metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
CA34196/CA/NCI NIH HHS; P30 CA034196-26S2/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 118072-93-8/zoledronic acid; 159351-69-6/everolimus; 53123-88-9/Sirolimus; EC 2.7.1.1/TOR Serine-Threonine Kinases; EC 3.6.5.2/ras Proteins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Persistence of seed-based activity following segmentation of a microRNA guide strand.
Next Document: Rec8-containing cohesin maintains bivalents without turnover during the growing phase of mouse oocyt...